Roberto Latagliata

Roberto Latagliata

UNVERIFIED PROFILE

Are you Roberto Latagliata?   Register this Author

Register author
Roberto Latagliata

Roberto Latagliata

Publications by authors named "Roberto Latagliata"

Are you Roberto Latagliata?   Register this Author

100Publications

2940Reads

22Profile Views

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Ann Hematol 2019 Aug 11;98(8):1891-1904. Epub 2019 May 11.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03706-xDOI Listing
August 2019

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Ann Hematol 2019 Aug 5;98(8):1919-1925. Epub 2019 Jun 5.

Hematology, Department of Precision and Translational Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03724-9DOI Listing
August 2019

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.

Hematol Oncol 2019 Jul 19. Epub 2019 Jul 19.

Hematology, Department of Translational and Precision Medicine, University 'Sapienza' and Policlinico Umberto 1, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2650DOI Listing
July 2019

Iron toxicity - Its effect on the bone marrow.

Blood Rev 2018 11 13;32(6):473-479. Epub 2018 Apr 13.

Independent Clinical Iron Expert, Via E.L.Cerva 200, 00143 Roma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.004DOI Listing
November 2018

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

Ann Hematol 2018 Oct 27;97(10):1803-1808. Epub 2018 May 27.

Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3375-9DOI Listing
October 2018

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Br J Haematol 2018 08 5;182(3):427-429. Epub 2017 Jul 5.

Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14783DOI Listing
August 2018

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol 2018 04 17;181(2):275-278. Epub 2017 Feb 17.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14560DOI Listing
April 2018

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.

Am J Hematol 2017 Dec 19;92(12):E661-E664. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24913
Publisher Site
http://dx.doi.org/10.1002/ajh.24913DOI Listing
December 2017

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Am J Hematol 2017 12 19;92(12):E668-E670. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24916DOI Listing
December 2017

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Am J Hematol 2017 Jan 12;92(1):37-41. Epub 2016 Nov 12.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology and Clinical Oncology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24572DOI Listing
January 2017

Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol 2016 06 25;173(6):945-6. Epub 2015 Aug 25.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13649DOI Listing
June 2016

The risk of infections in patients with myelodysplastic syndromes in 2016.

Expert Rev Hematol 2016 Jun 5;9(6):607-14. Epub 2016 May 5.

b Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I , 'Sapienza' Università of Rome , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2016.1181540DOI Listing
June 2016

Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes.

J Diabetes 2015 Jul 3;7(4):493-6. Epub 2014 Oct 3.

Hematology Unit, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1753-0407.12203DOI Listing
July 2015

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.

Am J Hematol 2015 May 30;90(5):E95-6. Epub 2015 Mar 30.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23972DOI Listing
May 2015

Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells.

Ann Hematol 2014 Nov 10;93(11):1819-23. Epub 2014 Jun 10.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2130-0DOI Listing
November 2014

Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.

Br J Haematol 2014 Nov 24;167(3):428-30. Epub 2014 Jun 24.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12995DOI Listing
November 2014

Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).

BioDrugs 2014 Feb;28(1):17-26

Hematology, S. Eugenio Hospital, Tor Vergata University, P. le dell'Umanesimo 10, 00144, Rome, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-013-0056-zDOI Listing
February 2014

Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients.

Leuk Res 2014 Feb 18;38(2):194-7. Epub 2013 Nov 18.

Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.11.008DOI Listing
February 2014

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

J Clin Oncol 2013 Dec 14;31(35):4424-30. Epub 2013 Oct 14.

Sergio Amadori and Adriano Venditti, Tor Vergata University Hospital; Paolo De Fabritiis, St Eugenio Hospital; Roberto Latagliata, University Sapienza; Paola Fazi and Marco Vignetti, Gruppo Italiano Malattie Ematologiche dell'Adulto, Roma; Franca Falzetti, University Hospital, Perugia; Domenico Magro, Pugliese Hospital, Catanzaro; Giorgina Specchia, University Hospital, Bari, Italy; Stefan Suciu and Matthias Karrasch, European Organisation for Research and Treatment of Cancer, Brussels; Dominik Selleslag, Algemeen Ziekenhuis St Jan, Brugge; Zwi Berneman, University Hospital, Antwerp, Belgium; Roberto Stasi, St George's Hospital, London, United Kingdom; Helmut R. Salih, University Hospital, Tubingen; Anthony D. Ho, University Hospital, Heidelberg; Michael Lübbert, Albert Ludwigs University, Freiburg, Germany; Petra Muus and Theo de Witte, Radboud University Medical Centre, Nijmegen; Constantijn J.M. Halkes and Roel Willemze, University Medical Center, Leiden, the Netherlands; Xavier Thomas, Edouard Herriot Hospital, Lyon; Jean-Pierre Marie, St. Antoine Hospital, Paris, France; and José E. Guimaraes, University Hospital, Porto, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.0771DOI Listing
December 2013

Management of acute promyelocytic leukemia in the elderly.

Mediterr J Hematol Infect Dis 2013 8;5(1):e2013045. Epub 2013 Jun 8.

Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy ; Laboratory of Neuro-Oncohematology, Santa Lucia Foundation, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2013.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736876PMC
August 2013

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

Haematologica 2012 Apr 18;97(4):560-7. Epub 2011 Nov 18.

Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerative, Azienda Policlinico Umberto I, Sapienza University of Rome Via Benevento 6, 00161 Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.053058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347676PMC
April 2012